Rifaximin (XIFAXAN) — Competitive Intelligence Brief

Rifaximin (XIFAXAN) (Rifaximin (XIFAXAN)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-absorbed rifamycin antibiotic. Area: Gastroenterology / Infectious Disease.

marketed Non-absorbed rifamycin antibiotic Bacterial RNA polymerase Gastroenterology / Infectious Disease Small molecule

Target snapshot

Rifaximin (XIFAXAN) (Rifaximin (XIFAXAN)) — University of California, San Francisco. Rifaximin is a non-absorbed antibiotic that inhibits bacterial RNA polymerase to reduce pathogenic gut bacteria without systemic absorption.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rifaximin (XIFAXAN) TARGET	Rifaximin (XIFAXAN)	University of California, San Francisco	marketed	Non-absorbed rifamycin antibiotic	Bacterial RNA polymerase
PB 6 doses - Rifampicin and Dapsone	PB 6 doses - Rifampicin and Dapsone	University of Brasilia	marketed	Antileprosy combination therapy	Bacterial RNA polymerase (rifampicin); dihydropteroate synthase (dapsone)
rifampin IV	rifampin IV	University of California, San Francisco	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
Rifaximin and loperamide	Rifaximin and loperamide	The University of Texas Health Science Center, Houston	marketed	Antibiotic + antidiarrheal combination	Bacterial RNA polymerase (rifaximin); mu-opioid receptors in the GI tract (loperamide)
Rifampicin alone	Rifampicin alone	Miguel Santín	marketed	Rifamycin antibiotic	Bacterial RNA polymerase β-subunit
Rifampicin Capsules	Rifampicin Capsules	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
Vancomycin plus Rifampin	Vancomycin plus Rifampin	Michael E. DeBakey VA Medical Center	marketed	Antibiotic combination	Bacterial cell wall (vancomycin) and bacterial RNA polymerase (rifampin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-absorbed rifamycin antibiotic class)

1. University of California, San Francisco · 1 drug in this class